CoChat
Sign Up
Cited by 438Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Open access
McGuire, Darren K., Marx, Nikolaus, Mulvagh, Sharon L., Deanfield, John E., Inzucchi, Silvio E., Pop-Busui, Rodica, Mann, Johannes F.E., Emerson, Scott S., Poulter, Neil R., Engelmann, Mads D.M., Ripa, Maria Sejersten, Hovingh, G. Kees, Brown-Frandsen, Kirstine, Bain, Stephen C., Cavender, Matthew A., Gislum, Mette, David, Jens-Peter, Buse, John B.·2025·New England Journal of Medicine
DOI 10.1056/nejmoa2501006
Open this paper in CoChat — free account

Abstract

BACKGROUND: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed. METHODS: In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis. The confirmatory secondary outcomes included major kidney disease events (a five-point composite outcome). RESULTS: Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months. A primary-outcome event occurred in 579 of the 4825 participants (12.0%; incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval, 0.77 to 0.96; P = 0.006). The results for the confirmatory secondary outcomes did not differ significantly between the two groups. The incidence of serious adverse events was 47.9% in the oral semaglutide group and 50.3% in the placebo group; the incidence of gastrointestinal disorders was 5.0% and 4.4%, respectively. CONCLUSIONS: Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2501006

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Magliano DJ, Boyko EJ. IDF diabetes atlas. 10th ed. Brussels: International Diabetes Federation, 2021.

Cited by

Sorted by citations

See all 438

Related

Metadata

Authors
McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., Ripa, M. S., Hovingh, G. K., Brown-Frandsen, K., Bain, S. C., Cavender, M. A., Gislum, M., David, J.-P., & Buse, J. B.
Affiliations
  • Parkland Health & Hospital System (US)
  • Universitätsklinikum Aachen (DE)
  • Dalhousie University (CA)
  • University College London (GB)
  • Yale University (US)
  • Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • University of Washington (US)
  • Imperial College London (GB)
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk, Søborg, Denmark
  • Swansea University (GB)
  • University of North Carolina at Chapel Hill (US)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2025-05-29
Volume
392
Issue
20
Pages
2001-2012
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa2501006
OpenAlex
W4408960945
Cited by
416
References
23
Citations by year
2026: 263 · 2025: 153
FWCI
283.71
Type
journal article
Language
en
Open access
Licence
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
Funders
Novo Nordisk (n/a)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
oral semaglutide, type 2 diabetes, major adverse cardiovascular events, atherosclerotic cardiovascular disease, chronic kidney disease, GLP-1 receptor agonists, cardiovascular safety, kidney disease progression, serious adverse events, gastrointestinal adverse effects, older adults, HbA1c, myocardial infarction, stroke, cardiovascular mortality
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Atherosclerosis, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review